|

GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders

RECRUITINGPhase 1Sponsored by Peking University First Hospital
Actively Recruiting
PhasePhase 1
SponsorPeking University First Hospital
Started2026-06-25
Est. completion2027-05-25
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted

Summary

This is a prospective, single-center, single-arm Phase I study evaluating GPRC5D-targeted PET/CT imaging in patients with plasma cell disorders, including multiple myeloma. Participants will undergo GPRC5D-targeted PET/CT, 18F-FDG PET/CT, and 68Ga-BCMA PET/CT within 5 days whenever feasible for head-to-head comparison of lesion detection and disease assessment. The study aims to evaluate the safety, feasibility, biodistribution, and diagnostic performance of GPRC5D-targeted PET/CT and to compare its imaging characteristics with currently available molecular imaging modalities in plasma cell disorders.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Adults with confirmed or suspected plasma cell disorders, including multiple myeloma.
* Healthy volunteers eligible for PET/CT imaging may also be enrolled.
* Availability of recent clinical laboratory results within 1 week prior to imaging, when applicable.
* Ability to undergo PET/CT imaging procedures.
* Ability to understand the study requirements and provide written informed consent.

Exclusion Criteria:

* History of other active malignant tumors, unless considered clinically insignificant by the investigator.
* Pregnant or breastfeeding women.
* Inability to understand study procedures or comply with imaging examinations.
* Any medical or psychiatric condition that, in the investigator's judgment, may interfere with study participation or image interpretation.

Conditions3

CancerMultiple Myeloma (MM)Plasma Cell Disorders

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.